a screaming buy, page-3

Well, I have gotten through over 70 Biopharma stocks listed on the ASX, and the only company trading less than cash backing is (you guessed it) BLT. Perhaps because it is the only real 'gene therapy' company.

What I found interesting in my search is that even companies that have less that $1 million in the bank, they are trading at between 3 and 20 times their cash backing and the prospects of these companies seem rather dire indeed.

Perhaps it is just my luck that I hold a substantial amount in the worst performing stock on the exchange, but something seems awfully fishy about this given that Benitec have $20million in the bank.

Perhaps it is because they only have an 'interim' CEO. But, at this stage, I see that as a plus as BLT are saving over $350,000 a year not having P. French sucking the life out of this company.

Anyway, I'm maintaining my 'screaming buy' rating, simply because it is an extremely enticing takeover opportunity for someone looking for easy cash and future R&D tax writeoffs even if nothing ever comes of the programs.